Form 4: Esperion Therapeutics Executive Eric Warren Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Chief Commercial Officer Eric Warren sold 211 shares of Esperion Therapeutics (ESPR) stock on August 19, 2024, to satisfy tax obligations related to vested restricted stock units.
Summary
- On August 19, 2024, Eric Warren, Chief Commercial Officer of Esperion Therapeutics, sold 211 shares of common stock.
- The sale was executed at a price of $1.946 per share.
- Following the transaction, Warren directly owns 165,267 shares of Esperion Therapeutics.
- The sale was conducted to cover tax obligations arising from the vesting of restricted stock units.
Sentiment
Score: 5
Explanation: The document itself is neutral, reporting a routine stock sale for tax purposes. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Insider trading activity is always closely watched by investors. While this sale appears to be for tax obligations, it will likely be scrutinized to ensure compliance with regulations and to assess management's confidence in the company's future prospects.
Stakeholder Impact
- The sale of shares by a company executive could be perceived negatively by some shareholders, even if it's for tax purposes, as it might signal a lack of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| February 28, 2022 | Date of execution of the Limited Power of Attorney. |
| 08/19/2024 | Date of the stock sale transaction. |
| 08/20/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.